Miltenyi Biotec, a Bergisch Gladbach, Germany-based company, announced on March 22 that it acquired lino Biotech. Miltenyi Biotec purchased 100% of the shares from investors such as Switzerland-based Roche Venture Fund and Germany-based Hightech-Grunderfonds.
Brown Gibbons Lang & Company initiated the transaction and acted as the exclusive financial advisor to lino Biotech.
lino Biotech is the world’s only company specialized in focal molography – a new method for measuring molecular interactions in living cells or crude biological samples. It is based in Zurich and was founded in 2020.
Miltenyi Biotec has been a global provider of products and services for biomedical research and cellular therapy for more than 30 years.
According to data captured in the LevinPro HC database, this acquisition represents the 39th Biotechnology transaction of the year.
